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The landscape of gestational diabetes mellitus (GDM) has remained 
dynamic, with the prevalence, definition, screening protocols, 
diagnostic criteria and therapeutic modalities continuously changing 
from as early as the 1960s. Most recently, GDM has been defined as 
a disorder of glucose intolerance first encountered during pregnancy 
that is not clearly overt diabetes.[1] GDM has far-reaching and well-
known ramifications for both mother and infant.[2] Global prevalence 
estimates are 16.9%,[3,4] with recent studies in South Africa (SA) 
showing prevalence figures ranging from 9.1% to 25.8%.[5,6]
Traditionally, GDM is initially managed with dietary and lifestyle 
interventions alone. However, insulin is introduced if glycaemic 
goals are not achieved.[7-9] Oral hypoglycaemic agents (OHAs) 
are an attractive alternative if lifestyle measures fail, particularly 
in resource-poor countries, because of their low cost and ease of 
administration. However, their use for GDM is surrounded by much 
debate regarding efficacy and safety, and they are recommended by 
some guidelines[9-11] and omitted in others.[12] One meta-analysis that 
included 13 studies utilising various diagnostic tests and criteria 
for GDM, with representation from both high- and low-income 
countries, investigated the safety of OHAs compared with insulin 
when treating GDM.[13] It demonstrated a higher preterm birth 
rate (relative risk (RR) 1.51) in patients exposed to metformin 
monotherapy, with a reduced risk of both gestational hypertension 
(RR 0.54) and lowered postprandial glucose levels. A further meta-
analysis of 15 studies showed an increased risk of macrosomia and 
neonatal hypoglycaemia in patients exposed to glibenclamide.[14] 
Research from SA has generally shown reassuring safety outcomes 
in terms of fetal anomalies and maternal glycaemic control for both 
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Background. Gestational diabetes mellitus (GDM), a disorder of glucose intolerance first encountered during pregnancy, has far-reaching 
implications for both mother and child. Insulin therapy remains the ‘gold standard’ of care, with oral hypoglycaemic agents (OHAs) 
increasingly being viewed as potential alternatives.
Objectives. To compare maternal and neonatal outcomes in two cohorts of women with GDM exposed to either insulin monotherapy or OHAs.
Methods. A retrospective medical record review at Chris Hani Baragwanath Academic Hospital in South Africa was conducted for women 
with GDM diagnosed using the 100 g oral glucose tolerance test and/or random capillary blood glucose >11.1 mmol/L in 2010 - 2014. 
The findings were compared with a previous audit at the same clinic for the period 1992 - 2002. Variables of interest included maternal 
demographics, maternal comorbidities, glycaemic indices, treatments used during pregnancy, and obstetric and neonatal outcomes.
Results. A total of 192 women with GDM were identified for 2010 - 2014, and there were 348 women in the previous audit (1992 - 2002). 
Baseline characteristics and outcomes of women in the two cohorts were similar apart from earlier presentation (mean (standard deviation) 
gestational age (GA) 27 (7.5) weeks v. 28.3 (6.4) weeks; p=0.04), lower GA at delivery (36.3 (3.6) weeks v. 37 (1.6) weeks); p=0.008) and lower 
macrosomia rates (12.5% v. 4.9%; p=0.011) in the later cohort. When comparing the individual OHAs against insulin in the later cohort, 
both agents were comparable to insulin in terms of maternal and neonatal outcomes.
Conclusions. This study contributes to the paucity of data on the safety of OHAs in GDM pregnancy in terms of maternal and neonatal 
outcomes. OHAs were shown to be an effective alternative to insulin for women with GDM in whom lifestyle measures fail, particularly in 
a resource-poor setting.
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metformin and glibenclamide in patients with both type 2 diabetes 
in pregnancy and GDM.[15,16] However, a recent study showed notably 
increased perinatal mortality (PNM) in type 2 diabetes patients 
exposed to glibenclamide, which could not be explained.[15]
Objectives
To compare the fetal and maternal outcomes of two cohorts of 
patients with GDM treated at Chris Hani Baragwanath Academic 
Hospital (CHBAH) in Johannesburg, SA, a decade apart, where 
the first cohort (1992 - 2002) was exposed to insulin monotherapy 
and the more recent group (2010 - 2014) to one or more treatment 
combinations including OHA monotherapy (metformin alone), 
OHA dual therapy (metformin plus glibenclamide), or insulin 
monotherapy. Furthermore, the outcomes in the 2010 - 2014 cohort 




This study retrospectively compared two cohorts of women attending 
the gestational endocrine clinic at CHBAH for GDM, the first 
between 1992 and 2002 and the second between 2010 and 2014. 
Characteristics and outcomes of the 1992 - 2002 cohort, where 
patients were exclusively exposed to insulin monotherapy, have been 
published previously[17] and are included for the purposes of the 
present study. A secondary analysis in the later cohort was performed 
with a medical record review of women exposed to OHAs v. insulin 
monotherapy, and their outcomes were compared.
CHBAH, a 3 000-bed teaching hospital with between 1 400 and 
1 600 deliveries per month, serves the population of the sprawling 
township of Soweto, SA, ethnically predominantly black. All patients 
with singleton pregnancies treated at CHBAH for GDM between 1992 
and 2002 and between 2010 and 2014, either diagnosed by random 
capillary blood glucose ≥11.1 mmol/L or fulfilling National Diabetes 
Data Group (NDDG) criteria following a 3-hour 100 g oral glucose 
tolerance test (OGTT), were included in the study. Both cohorts 
had similar screening strategies for GDM. Participants with twin 
pregnancies and other subtypes of diabetes, including pregestational 
diabetes, pancreatic diabetes and steroid-induced diabetes, were 
excluded. A control group was defined as patients who presented 
after 36 weeks’ gestational age (GA) or received <2 weeks of medical 
intervention, and these patients were excluded for the purposes of 
the study. The study protocol was approved by the Human Research 
Ethics Committee of the University of the Witwatersrand (ref. no. 
M180316).
Definitions
Diabetes was considered gestational if the diagnosis was first made 
during pregnancy in women referred because of the presence of risk 
factors for diabetes: persistent glycosuria, first-degree family history 
of diabetes, previous unexplained perinatal losses, previous GDM, 
or history of a macrosomic baby. Selective screening for GDM was 
performed between 24 and 28 weeks’ GA. GDM was diagnosed 
using a 100 g 3-hour OGTT and NDDG criteria, which required 
two or more of the following plasma glucose levels for the diagnosis 
of GDM: fasting plasma glucose (FPG) ≥5.8 mmol/L, 1-hour post-
glucose load ≥10.6 mmol/L, 2-hour post-glucose load ≥9.2 mmol/L, 
or 3-hour post-glucose load ≥9.2 mmol/L. GDM was classified as 
‘overt’ if the baseline FPG was ≥7.0 mmol/L.
Maternal characteristics and outcomes were defined as follows. 
GA was determined using an early ultrasound scan. Glycaemic 
control: mean blood glucose (MBG) <7.1 mmol/L for the third 
trimester, calculated as a mean of daily self-monitored six-point 
profiles, including both fasting and 1-hour post-prandial. Dietary 
failure: failing to achieve glycaemic control after 2 weeks of 
dietary intervention. Diabetic nephropathy: microalbuminuria, 
with a microalbumin-creatinine ratio >30 mg/mmol on repeated 
testing, in the absence of urinary tract infection and other renal 
disease. Body mass index (BMI): the patient was considered obese 
if the BMI was >30 kg/m2 at the first visit. Anaemia: haemoglobin 
concentration <11 g/dL. HIV-positive: based on results from rapid 
or antibody tests before or at the time of initial presentation. 
Obstetric complications included premature labour, caesarean 
section (CS), miscarriage, hypertensive disorders of pregnancy 
(HDP), urinary tract infection, polyhydramnios, oligohydramnios 
and maternal death. Hypertension was diagnosed when blood 
pressure readings were elevated (>140/90 mmHg) for at least two 
measurements. This was further categorised into HDP and chronic 
hypertension. HDP was further classified into pregnancy-induced 
hypertension (PIH), where hypertension developed after 20 weeks 
of pregnancy, pre-eclampsia, where PIH was found in the presence 
of proteinuria on more than one occasion, and eclampsia, where 
PIH was found in the presence of proteinuria and seizures. Chronic 
hypertension was defined as hypertension diagnosed prior to 
the pregnancy. Maternal hypoglycaemia was defined as one or 
more episodes of hypoglycaemia severe enough to necessitate the 
administration of intravenous dextrose.
Neonatal outcomes were defined as follows. Prematurity/preterm 
birth: delivery at <37 completed weeks’ GA. Miscarriage: loss in 
pregnancy occurring at <28 completed weeks’ GA. Stillbirth: loss 
in pregnancy occurring at ≥29 weeks’ GA. Early neonatal death: 
neonatal death occurring in the first week. PNM: the number of 
stillbirths and early neonatal deaths out of the total number of 
deliveries (successful deliveries and stillbirths). Low birth weight 
(LBW): birth weight <2 500 g. Macrosomia: birth weight ≥4 000 g. 
Major congenital anomalies: spinal, cardiac, central nervous system, 
renal or digestive system anomalies.
Definitions applied to both study cohorts except for MBG and 
nephropathy, where the MBG in the earlier cohort was calculated 
as a mean of the fasting and 1-hour plasma glucose levels, and 
nephropathy was defined as dipstick urinalysis positive for proteinuria 
(protein >0.3 g/L) on repeated testing.
Clinical practice
The specialist clinic at CHBAH was established in 1983 and is staffed 
by a physician, an obstetrician, a paediatrician and a diabetes nurse 
educator. The initial visit comprised a full clinical assessment with 
ultrasound and treatment initiation. Initial ultrasound was used to 
assess GA and to rule out any major fetal anomalies. All patients 
were screened for target organ damage, including retinopathy and 
nephropathy. Newly diagnosed women with GDM (as per the NDDG 
criteria) were hospitalised for glycaemic stabilisation. Patients were 
taught blood glucose monitoring by the nurse educator. Fingerprick 
capillary blood samples were obtained using lancets, and blood 
glucose levels were read using various glucometers for the later 
cohort. In the earlier cohort, glucose levels were read visually using 
Haemo-glukotest 20-800R strips (Roche Diagnostics, Germany). 
Dietary advice was provided on an ongoing basis by a dietician and/
or a nurse educator, with a 2-week trial of dietary monotherapy being 
prescribed where the fasting glucose level was <7.0 mmol/L. For the 
period 1990 - 2010, insulin monotherapy was prescribed in the event 
of dietary failure. From 2010 onward, OHAs (metformin and/or 
glibenclamide) were introduced as follows: metformin monotherapy 
was prescribed in the event of dietary failure, then therapy was 
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escalated with either the addition of glibenclamide or a switch to 
insulin monotherapy. Insulin was initiated at the outset in patients 
whose fasting glucose exceeded 7.0 mmol/L or if maternal or fetal 
complications were present. Glycaemic targets were <5.3 mmol/L for 
fasting glucose and <7.8 mmol/L for a 1-hour postprandial reading 
for the later cohort, levels between 4 and 7 mmol/L being accepted 
for the earlier cohort. Combined MBG, which included an average 
of the fasting and 1-hour postprandial readings of <7.1 mmol/L, was 
included to assess glycaemic control as per institutional practice. 
Patient-monitored daily six-point profiles were also assessed based 
on Society for Endocrinology, Metabolism and Diabetes of South 
Africa (SEMDSA) criteria.[11,18]
Following the initial assessment, patients were seen fortnightly or 
sooner if indicated. At each visit, patients were clinically assessed, the 
results of home blood glucose monitoring were noted, and treatment 
was adjusted if necessary. Ultrasound scans were repeated at intervals 
to assess fetal growth and anomalies. A point-of-care glycated 
haemoglobin (HbA1c) test was performed monthly using the DCA 
Vantage Analyzer (Siemens, Germany), which had been standardised 
and was traceable to the Diabetes Complications and Control Trial. 
All patients had an HbA1c test within a month prior to delivery. 
After 32 weeks’ GA the visits were weekly until 37 - 38 completed 
weeks, when labour was induced. Time and mode of delivery were 
dictated by obstetric factors and glycaemic control, with the goal of 
38 completed weeks of pregnancy unless complications arose. During 
labour, glucose levels were monitored hourly and controlled using 
dextrose-insulin infusions. Oral and/or insulin therapy was stopped 
postpartum, and only reinitiated based on results from inpatient self-
glucose monitoring. All GDM patients not requiring ongoing therapy 
were asked to return for a 6-week 75 g OGTT at the maternity clinic. 
All neonates were assessed for clinical or biochemical abnormalities 
by paediatric staff in the neonatal unit and managed accordingly.
The control group defined above was excluded for the purposes 
of this study.
Statistical analysis
Data were captured and entered directly into an electronic database 
(REDCap, USA), cleaned and imported into Stata 13 (StataCorp, 
USA) for statistical analysis. Comparison of the 1992 - 2002 v. 
2010 - 2014 cohort was expressed as numbers and percentages for 
categorical variables and means and standard deviations (SDs) for 
continuous variables. Comparisons between the two cohorts were 
made using an online statistical calculator, MedCalc (version 16.4.3; 
www.medcalc.org), where a χ2 test was used for categorical outcomes 
and a t-test was employed for the purpose of continuous variables, to 
determine statistical significance.
Baseline characteristics of the 2010 - 2014 cohort were described 
using numbers and percentages for categorical variables and, 
depending on normality, means and SDs or medians and interquartile 
ranges (IQRs) for continuous variables. To test for normality, a 
skewness-kurtosis test was performed if the mean and median were 
substantially different. Statistical significance testing in the 2010 - 
2014 group was done using Student’s t-test or the non-parametric 
Mann-Whitney U-test for continuous outcomes, and a χ2 statistic 
or Fisher’s exact test for categorical outcomes. For analysis across 
more than two groups, analysis of variance (ANOVA) or the non-
parametric Kruskal-Wallis test was used. Statistical significance was 
set at p<0.05.
Results
Comparison of the two cohorts of GDM patients
Maternal profiles
Table 1 presents maternal profiles of the 348 GDM patients in the 
period 1992 - 2002 and the 192 GDM patients in the period 2010 - 
2014. The two cohorts were comparable in terms of maternal age at 
presentation, overall rates of hypertension (20.7% v. 14.4%; p=0.06) 
and the significant decrease from HbA1c at first booking to HbA1c 
within a month of delivery (earlier cohort mean (SD) 7.1% (1.7) 
to 6.6% (1.2); p=0.0001 and later cohort 7.8% (1.8) to 7.1% (1.4); 
Table 1. Comparison of maternal characteristics, glycaemic control and outcomes between 1992 - 2002 and 2010 - 2014 gestational 
diabetes mellitus cohorts diagnosed by 100 g oral glucose tolerance test and random capillary blood glucose
1992 - 2002 cohort (N=348) 2010 - 2014 cohort (N=192) p-value
Maternal characteristics 
Maternal age at initial presentation (years), mean (SD) 33.9 (5.2) 33.0 (5.2) 0.06
GA at first presentation (weeks), mean (SD) 28.3 (6.4) 27.0 (7.5) 0.04*
Hypertension,† n (%) 50 (14.4) 39 (20.7) 0.06
Target organ damage, n (%)
Retinopathy 5 (1.4) 2 (1.05) 0.72
Diabetic nephropathy 1 (0.3) 0 -
Glycaemic control and therapeutics
HbA1c (%), mean (SD), at
First booking 7.1 (1.7) 7.8 (1.8) -‡
Within a month of delivery 6.6 (1.2) 7.0 (1.2) -‡
Controlled by third trimester (by MBG), n (%) - 139 (85) -
Dietary therapy alone, n (%) 17 (4.9) 4 (2.1) 0.182
OHA exposure, n (%)
Metformin n/a 84 (43.7) -
Glibenclamide n/a 46 (23.4) -
Switched from OHA to insulin n/a 15 (7.8) -
Controlled by delivery on OHA alone, n (%) n/a 59 (95) -
Insulin monotherapy, n (%) 331 (95.1) 99 (52.6) <0.0001*
GA = gestational age; SD = standard deviation; HbA1c = glycated haemoglobin; MBG = mean blood glucose; OHA = oral hypoglycaemic agent; n/a = not applicable.
*Statistically significant (p<0.05).
†Includes all forms of hypertension noted in pregnancy.
‡p-value omitted given different methodologies utilised for measuring HbA1c between the two groups.
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p=0.000). In the later cohort, first presentation was earlier (mean 
(SD) 27 (7.5) weeks v. 28 (6.4) weeks; p=0.04), and >85% of all 
patients in this cohort achieved their glycaemic goals as measured by 
their MBG for the third trimester, with >95% of those on oral agents 
alone achieving good control by delivery. Failure rates for dietary 
monotherapy were high for both cohorts (97.9% v. 95.1%). The need 
for insulin monotherapy was lower for the later cohort than for the 
earlier cohort (52.6% v. 95.1%).
Maternal and neonatal outcomes (Table 2)
GA at delivery in the recent cohort was lower (mean (SD) 36.4 (3.65) 
weeks v. 37 (1.6) weeks; p=0.008), with a higher number of preterm 
deliveries. Birth weight and macrosomia rates were statistically lower 
in the most recent cohort (3 017 (648) g v. 3 204 (657) g; p=0.002 and 
12.5% v. 4.9%; p=0.01, respectively). PNM was comparable between 
the cohorts (4.2% v. 4.9%; p=0.72), with fewer stillbirths and a non-
significant increase in early neonatal deaths in the recent cohort.
Effect of oral agents on maternal and neonatal  
outcomes in the 2010 - 2014 cohort
In the 2010 - 2014 cohort, ‘overt’ GDM was diagnosed in 43.8% 
of patients based on a baseline FPG ≥7.0 mmol/L. The mean (SD) 
FPG at first visit for the cohort was 7.3 (2.14) mmol/L. Ninety-nine 
patients (53.8%) required insulin monotherapy at first diagnosis, 
with 45.0% requiring OHAs and 2.1% dietary monotherapy. Of those 
initiated on diet alone, 97.8% failed and required a switch to OHAs. 
Eighty-four patients (43.7%) were exposed to metformin and 45 
(23.4%) to glibenclamide, with 7.8% of the OHA group requiring a 
switch to insulin. Within the cohort treatment groups, no significant 
differences were observed in maternal age and BMI in the groups 
exposed to OHA compared with insulin monotherapy. For the 
insulin- v. glibenclamide-exposed groups, initial HbA1c (median 
(IQR) 8.9% (7.2 - 10.1) v. 6.7% (6.3 - 7.1); p=0.001) and weight gain 
during pregnancy (median 5 (2.2 - 9.6) kg v. 2 (0 - 4) kg; p=0.00) were 
significantly higher in the insulin group.
Of the 192 files recorded, outcomes were available for 162 patients, 
given a 16.7% loss-to-follow-up rate. There were no differences 
in maternal and neonatal outcomes in terms of each oral agent v. 
insulin. When comparing metformin with insulin, the incidences of 
prematurity, macrosomia, LBW and PNM were all non-significantly 
lower with metformin therapy. Outcomes for the glibenclamide- 
v. insulin-exposed groups were comparable, including rates of 
macrosomia (11.4% v. 3.3%; p=0.19) and LBW (22.2% v. 14.6%; 
p=0.35). CS rates, although not different among the groups, were 
high (78.6%, 77.7% and 64.7%, respectively), with failed induction of 
labour being the commonest indication. No maternal mortality was 
reported for the cohort.
Discussion
In this comparative study: (i) lower macrosomia rates and earlier 
GA at delivery were found in the later cohort exposed to both OHA 
and insulin therapy (2010 - 2014) v. the earlier cohort (1992 - 2002) 
exposed to insulin monotherapy; (ii) effectiveness of OHAs was 
evident in terms of the low number of patients who needed to be 
switched to insulin; and (iii) maternal and neonatal outcomes were 
comparable in the group exposed to OHAs and those exposed to 
insulin alone for the 2010 - 2014 cohort.
When comparing the historical cohorts, the introduction of 
OHAs in the later cohort was effective in achieving good glycaemic 
control at delivery, with favourable and comparable maternal and 
neonatal outcomes, including maternal hypoglycaemia, CS rates, 
macrosomia, major congenital anomalies and PNM, in women 
treated with OHAs. This finding is of public health relevance in 
SA, where limited resources and access to specialised care for 
GDM often translate into adverse outcomes, because it provides 
healthcare professionals with a cost-effective and less complex 
alternative to the ‘gold standard’ of care, insulin, with a similar 
safety profile.
Of interest were the lower birth weights and macrosomia rates in 
the cohort exposed to OHAs. One plausible explanation is the earlier 
GA at delivery, which may have numerous contributing factors. 
Metformin has been found to be protective against macrosomia 
in some studies,[19,20] although this was not evident in our study 
when metformin monotherapy was compared with insulin alone; 
however, numbers were small for this comparison. Our study did not 
corroborate a finding from a robust meta-analysis, including seven 
randomised controlled trials, of a significant relationship between 
glibenclamide exposure and higher birth weights, macrosomia rates 
and neonatal hypoglycaemia compared with insulin therapy.[14]
Lastly, PNM did not differ between the two cohorts (4.2% v. 4.9%; 
p=0.72), and no higher PNM was found in the OHA-exposed group. 
This PNM figure, while higher than the national rate of 3.3%[21] for 
all pregnancies, compares favourably with a recent audit of diabetic 
pregnancies from Cape Town[22] and those from elsewhere in Africa, 
which range from 5.2% to 25.4%.[23]
In the 2010 - 2014 cohort, GDM was detected earlier, possibly 
as a result of improved awareness both among the public and in 
the public health system through enhanced screening protocols at 
both primary- and secondary-level clinics. However, the high mean 
HbA1c at booking raises concern that many of the women had pre-
gestational diabetes that had not been diagnosed before pregnancy, 
highlighting a potential gap in the diabetes screening programmes. 
Furthermore, this burden of type 2 diabetes mellitus occurs alongside 
a rising prevalence of obesity,[24] as is appreciated in the recent cohort, 
with 81.4% of the women having a BMI >30 kg/m2. Despite this high 
Table 2. Maternal and neonatal outcomes for the 1992 - 2002 and 2010 - 2014 gestational diabetes mellitus cohorts
1992 - 2002 cohort (N=348) 2010 - 2014 cohort (N=164) p-value
GA at delivery (weeks), mean (SD) 37.0 (1.6) 36.4 (3.6)  0.008*
Live births, n (%) 344 (98.8) 161 (98.3)  0.65
Caesarean section, n (%) 215 (61.8) 113 (68.7) 0.10
Maternal hypoglycaemia, n (%) 3 (0.9) 1 (1.0) 0.87
Birth weight (g), mean (SD) 3 204 (657) 3 017 (648) 0.002*
Macrosomia, n (%) 43 (12.5) 7 (4.9) 0.011*
Stillbirths, n (%) 10 (2.8) 3 (1.8) 0.49
Early neonatal deaths, n (%) 5 (1.4) 5 (3.1) 0.193
PNM, n (%) 15 (4.2) 8 (4.9) 0.72
GA = gestational age; SD = standard deviation; PNM = perinatal mortality.
*Statistically significant (p<0.05).
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rate of obesity, most of our patients attained good glycaemic control 
by the third trimester (>85%), with similar outcomes to studies both 
internationally and locally.[19,20]
In the recent cohort, over half of the patients (53.8%) required 
insulin from their first visit owing to the severity of their initial 
dysglycaemia, explained by the fact that close to 50% of the cohort had 
‘overt’ diabetes. In the patients initiated on OHAs, the effectiveness of 
these agents in this group was evident in the small number of patients 
who needed to be switched from OHA to insulin (7.8%), and the good 
glycaemic control at delivery. Notably, both cohorts demonstrated 
high dietary failure rates compared with figures elsewhere (95.1% 
and 97.9% v. 20.0 - 30.0%),[12] which is probably due to the presence 
of more severe cases of dysglycaemia (as indicated by the high initial 
HbA1c) because of risk factor-based screening rather than universal 
screening. Furthermore, financial challenges encourage patients to 
consume a carbohydrate-rich diet as opposed to fully embracing 
the proposed diet. Lastly, this discordance in the percentage of 
patients failing dietary measures may be attributed to differences in 
definitions of glycaemic control, population characteristics and the 
population responses.
Study limitations and strengths
Limitations of the current study include its retrospective nature and 
small numbers of patients in the cohorts. The diagnostic criteria 
employed, although relevant at the time, are no longer applicable and 
may limit reproducibility of the study. Furthermore, comparison of 
certain variables between the two cohorts was limited. We did not 
have access to the earlier cohort’s database and hence could not merge 
the insulin monotherapy group with the later cohorts for the purposes 
of analysis. In addition, the definitions of nephropathy and the MBG 
calculations were different. Different assays for HbA1c were used 
at the two time points, with an immunoassay (Roche Diagnostics, 
Germany) being performed on whole blood by the National Health 
Laboratory Service in the earlier cohort and point-of-care testing 
being employed in the later cohort, making comparison of HbA1c 
between the cohorts problematic. As the prevalence rate of anaemia 
in the later cohort was high (11%), decreased reliability of this test 
cannot be ruled out. Comparison of maternal and neonatal outcomes 
between cohorts was restricted to the variables obtained for the 
earlier cohort. This prevented us from exploring whether the lower 
GA at delivery in the recent cohort may have translated into more 
cases of prematurity. Various confounders for outcomes were either 
poorly reported, like BMI, or not at all, like HIV status, in one or 
both of the cohorts. Strengths of the study include the comparison of 
patients from the same clinic 10 years apart, diagnosed utilising the 
same test and criteria, where the only difference was the introduction 
of oral hypoglycaemic agents.
Conclusions
After the introduction of OHAs at the CHBAH gestational endocrine 
clinic, patients achieved similar levels of glycaemic control at delivery 
and showed similar outcomes compared with patients receiving 
insulin therapy. This is reassuring, particularly for low- and middle-
income countries, where the OHAs are cheaper, more accessible, 
easier to use and eliminate the availability and storage issues 
associated with insulin therapy. Further prospective studies with 
adequate sample sizes are needed to confirm our findings and to 
determine the impact of OHA on pregnancy outcomes, both in the 
short and long term.
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